Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07491445 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Study acronym: RASolute 303
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 61 → 82 locations Trial sites expanded: 49 → 61 locations Show 1 more changeShow less
    • Trial sites expanded: 49 → 61 locations
  2. Study sites: 49 to 61 Eligibility criteria expanded, about 13 words · Secondary endpoints: details revised at 2 of 8 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 2 of 8 entries
  3. Trial sites expanded: 33 → 49 locationsv11
  4. Trial sites expanded: 25 → 33 locationsv10
  5. Trial sites expanded: 20 → 25 locationsv9
  6. Trial sites expanded: 13 → 20 locationsv8
  7. Trial sites expanded: 8 → 13 locationsv7
  8. Trial sites expanded: 5 → 8 locationsv6
  9. Study sites: 3 to 5v5
  10. Re-verified, no change to tracked fieldsv4
  11. Study sites: 2 to 3v3
  12. Secondary endpoints: details revised at 3 of 8 entriesv2
  13. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
Trial Details
NCT Number NCT07491445
Lead Sponsor Revolution Medicines, Inc.
Conditions Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
Enrollment 900 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov